During the past grant period, developmental funds supported the recruitment of 20 productive Consortium faculty members in areas of strategic growth, including 12 clinical investigators working on solid-tumor cancer;44 pilot projects resulting in the acquisition of 27 grants and the publication of 34 papers;and the development of three shared resources in Imaging, High Throughput Genetics and Immune Monitoring. In this competing application, developmental funds are also requested for activities in these three areas as summarized below: 1. Faculty recruitment: CCSG funds are requested to support funding for five new recruits per year in areas of high strategic importance to the Consortium. The Consortium typically recruits 10 to 20 new members per year. 2. Pilot projects: CCSG funds are requested to fund nine to 11 pilot research projects of Consortium members each year. 3. Shared resources: Funding is requested for four shared resources of critical need to Consortium investigators - Bioinformatics;High Throughput Screening, Tissue Bank, and Tumor Models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-39
Application #
8561892
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$2,128,691
Indirect Cost
$811,983
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Morris, S M; Carter, K T; Baek, J Y et al. (2015) TGF-? signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene 34:3273-82
Briant, Katherine Josa; Espinoza, Noah; Galvan, Avigail et al. (2015) An innovative strategy to reach the underserved for colorectal cancer screening. J Cancer Educ 30:237-43
Toledo, Chad M; Herman, Jacob A; Olsen, Jonathan B et al. (2014) BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Dev Cell 28:282-94
Klippel, Z K; Chou, J; Towlerton, A M et al. (2014) Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 21:337-42
Mielcarek, Marco; Kirkorian, Anna Yasmine; Hackman, Robert C et al. (2014) Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. Transplantation 98:563-8
Luo, Yanxin; Wong, Chao-Jen; Kaz, Andrew M et al. (2014) Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147:418-29.e8
Cermelli, Silvia; Jang, In Sock; Bernard, Brady et al. (2014) Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4:
Rizzardi, Anthony E; Rosener, Nikolaus K; Koopmeiners, Joseph S et al. (2014) Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 14:244
Vainstein, V; Buckley, S A; Shukron, O et al. (2014) Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 28:713-6
Laszlo, George S; Ries, Rhonda E; Gudgeon, Chelsea J et al. (2014) High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 55:2817-21

Showing the most recent 10 out of 300 publications